CN1169575C - Human tumor necrosis factor-alpha oral prepn. of marine polychlorella - Google Patents

Abstract

The present invention relates to a human tumor necrotic factor alpha oral preparation which comprises marine blue alga capable of expressing person tumor necrotic factor alpha. The oral preparation of the present invention can directly act on tumors of a digestive tract.

Description

Orally applied medicine containing Nostoc which expressing human tumor necrosin factor alpha with the preparation of ocean Synechococcus

(1) technical field

The present invention relates to a kind of oral agents, specifically, the present invention relates to a kind of Orally applied medicine containing Nostoc which expressing human tumor necrosin factor alpha with the preparation of transgenic Synechococcus.

(2) background technology

Tumor necrosis factor (Tumor Necrosis Factor α is called for short TNF α) is a kind of multifunctional cytokine that is produced by activated mononuclear phagocyte.People's activated TNF α is that the non-glycoprotein monomer of 17KDa constitutes monomer and is the lamella foldable structure by 3 molecular weight, between them by the non-covalent composition body of disulfide bond between a Cys69-Cys101.The TNF α in different genera mammal source has high homology on primary structure, also do not have tangible species specificity on biologic activity.The TNF α isoelectric point, IP of purification is about 5.3; Stable during pH6-8; Acid labile: to proteolytic enzyme (trypsin, rotten albumen etc.) sensitivity; 50% saturated ammonium sulfate can make its precipitation.When multigelation and unprotect agent, inactivation under the room temperature.

TNF α gene is a single copy gene.People's gene size is 2.67kb, is positioned No. 6 chromosome of people.Genome is made up of 4 exons and 3 introns; Precursor protein, its preceding 76 aminoacid of being made up of 233 aminoacid of encoding are signal peptide, make before the TNF α physical ability stride film is present on the cell, after degraded, tells and contains 157 amino acid whose maturation proteins, non-glycosylated.Show in the signal peptide of coding 81%, the 4th exons coding 89% adult form TNF alpha amino acid sequence outside the human TNF alpha gene the 1st.

With TNF α to tumor do clinical immunization therapy be develop faster novel anti tumor therapy for over ten years, be effectively to replenish to conventional meanses such as clinical operation, radiotherapy, chemotherapy.This has all obtained progress preferably in the U.S., Japan and Germany.The Genentech company of the U.S. occupies first place with aspects such as TNF α treatment breast carcinoma, pulmonary carcinoma, colon cancer in clinical trial; Cetus company has started compound bio reaction control agent method to TNF α and IL-2 coupling.The recombinant product of Japan has entered clinical trial, and breast, ascites metastatic carcinoma in late period, colorectal cancer, carcinoma of gallbladder etc. have been obtained good progress.Germany BASF AG produces per year can reach 500g, and Germany has obtained success with TNF α at aspects such as gastroenteric tumor, hepatocarcinoma, ovarian tumor, breast carcinoma, and especially the curative effect aspect the control cancerous ascites pleural fluid is at the forefront in the world.5 of approved Shanghai, Xi'an tame units begin clinical trial at the beginning of China's Ministry of Public Health 1998.

Route of administration mostly is vein, muscle and subcutaneous injection in one's early years clinically, in order to alleviate the toxicity of TNF α, often adopts local injection or regional perfusion's method in recent years, in the treatment, late tumor.Dosage is from 10 μ g/m ²To 400 μ g/m ²More therapeutic scheme is to be 1 course of treatment in 2 weeks, and 50 μ g/m are given in administration in continuous 5 days in each course of treatment every day ²Dosage depends primarily on drug effect, common 800,000 units/m ²Effectively.

Though separated in 1975, purification TNF α, and illustrated structure, obtained the recombinant product of TNF α in 1985 with the bacillus coli gene engineering; But TNF α also rests on clinical stage so far, and the medical administrative department of countries in the world does not all ratify TNF α as commercially available medicine, sells on market.This finds that TNF α has serious general toxicity effect mainly due to from initial clinical trial the time, and is higher 20 times than mice to people's toxic action.

This toxic action mainly shows: heating (35-100%), shiver (70-100%), the headache (20-70%) of feeling sick.Weak (20-77%), appetite decline (24-46%); Also suffer from diarrhoea, blood platelet reduction, leukopenia, GTP rising, fluid retention, myalgia, even endotoxin shock.The clinical practice dosage that this just limits the TNF α that knows clearly greatly has a strong impact on the effect that it treats tumor.

So far can be optionally, again the direct killing tumor medicine seldom, the mortality rate of cancer still is higher than other various diseases.TNF α is found the back, and everybody entertains great hope to it.But systemic-toxic seriousness has limited its application.The various countries scholar is reducing the toxicity of TNF α by every possible means for over ten years, has mainly obtained some progress from two aspects: first aspect is to change before and after the route of administration .1990, and the U.S. once tested and uses gene therapy, promptly TNF α was directly injected tumor tissues.Second aspect is with protein engineering the structure of TNF α to be transformed, and the purpose that changes structure is to reduce toxicity and improve antitumor.The suddenlyd change success for over ten years derivant of tens of kinds of TNF α, wherein some toxicity has obvious must decline, and anti-tumor activity is significantly increased.Even so, various countries are still also doing clinical trial.

(3) summary of the invention

At the problems referred to above of present existence, the present invention has adopted the engineered method of cyanophyceae to produce tumor necrosis factor with marine cyanobacterium the host who serves as reorganization TNF α.With reduction toxicity, and can directly act on gastral tumor.

The invention provides a kind of Orally applied medicine containing Nostoc which expressing human tumor necrosin factor alpha, contain the ocean Synechococcus of expressing human tumor necrosis factor (hTNF α).

In the oral agents of the present invention, described marine cyanobacterium is ocean Synechococcus 7002 (Synecoccocus sp.PCC 7002).The cDNA of this tumor necrosis factor of described coding (hTNF α) can have nucleotide sequence as shown in Figure 1.TNF α cDNA shown in Figure 1 has 6 bases different with original:

Aminoacid	Val	Arg	Ser	Arg	Gln
						Base in the cyanophyceae	GT T	CG T(128，130)	TC T(133)	CGT(142)	GAG(561)
Base in the human body	GTC	AGA	TCA	CGA	CGA

In the oral agents of the present invention, the ocean Synechococcus of described expressing human tumor necrosis factor can be CGMCC 0499.

The consumption of oral agents of the present invention is counted everyone (adult) 5-500 every day μ g with pure TNF α, preferred 50-300 μ g, more preferably 100-200 μ g.

Characteristics of the present invention are to utilize cyanophyceae as the host, and it does not contain endotoxin, produce recombinant product with it as the host and can simplify lower procedure.The characteristics that the present invention also has are, itself contains rich nutrient contents cyanophyceae, so be that the TNF α that produces of host can be directly oral after through thick the extraction with the cyanophyceae.Help the absorption of medicine, overcome many shortcomings of injection drug.Another characteristics of the present invention are that the oral agents of preparation is very stable.At room temperature placed 15 days, active uninfluenced.And the injection that purification is made can only be preserved at low temperatures, uses inconvenient.

(4) Brief Description Of Drawings

Fig. 1 is the hTNFcDNA nucleotide sequence in the Synechococcus of ocean

The ocean Synechococcus of the commentaries on classics hTNF-α gene that obtains according to the present invention is deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center (CGMCC) (China, Beijing, Zhong Guan-cun) on October 20th, 2000, and preserving number is CGMCC 0499.

(5) specific embodiment

Embodiment:

One bacterial strain and vector plasmid

1. cyanophyceae algae kind: ocean Synechococcus Synecoccucs sp.PCC 7002 is provided by Pasteur Institut.

2. coli strain: Escheichia.coli HB101 is as the recipient bacterium that transforms plasmid.

3. plasmid:

(1) pRL-TC makes up the multiple clone site that (Liu Fenglong etc., Chinese science (C collects) 29 (2), 217,1999) inserts rhTNF plasmid pRL439 by this laboratory.Have psbA promoter, ampicillin resistance gene and non-impaired bom district (transfer required area) on the pRL439

(2)pKR-210(Bagdesarian M.，Ruckert B.Et al.Gene.1981，16：237-247。

(3) RP4+pRL542 in E.coliHB101 (Liu Fenglong etc., Chinese science (C collects) 29 (2), 217,1999) is a kind of helper plasmid.

The cultivation of two ocean Synechococcus

Cyanophyceae generally is incubated in the fluid medium, places Gallenkamp type illumination cooling rotating and culturing case shake to cultivate, rotating speed 130rpm, and 25-30 ℃, changed a culture fluid in 10 days, go down to posterity with inoculation in 1: 50.

Can adopt the line separation during purification algae kind and be coated with isolating method.Containing on the solid medium flat board of 1.5% agar, be inverted irradiation and cultivate, waiting to occur single algae and fall behind, light microscopic is confirmed the algae kind down, repeats the purification of ruling.

Solid plate is more suitable for the preservation of cyanophyceae algae kind.Flat board is placed under the low light level, and room temperature can be preserved 3-6 month.Liquid culture is statically placed under the room temperature low light level, and two weeks were changed a culture fluid.Collect 10 days cyanophyceae culture, add sterile glycerol (final concentration is 30%), can preserve more than 2 years for-70 ℃.

Change the ocean Synechococcus of hTNF-α gene and cultivate in the BG-11 culture fluid that contains ammonia benzyl mycin 25 μ g/ml and streptomycin 15 μ g/ml, cultural method is identical with general cyanophyceae.

The building process of three shuttle expression carrier pIB-01 (pKT-TNF)

The building process of shuttle expression carrier pIB-01 mainly divided for 2 steps: the pRL-rhTNF plasmid that 1) contains reorganization hTNF α cDNA total length is through the XhoI enzyme action, after mending flat 3 '-end under the effect of Klenow enzyme, continue and digest with EcoR I, recovery comprises the 700bp fragment of hTNF α cDNA, this fragment orientation is inserted among the SmaI and EcoRI site that follows closely on the pRL-439 carrier after the promoter PpsbA, and the recombiant plasmid that so obtains is named and is pRL-TC; (2) digest pRL-TC and pKT-210 respectively with EcoR I single endonuclease digestion, fragment that contains PpsbA and hTNF α cDNA about the 800bp of recovery pRL-TC and the 9.0kb fragment of pDC-8 obtain shuttle expression carrier pIB-01 after the connection.

Four transform and screening ocean Synechococcus

1. transform the ocean Synechococcus with three close conduction methods

A. colibacillary preparation:

Contain in the corresponding antibiotic LB culture fluid inoculation at 20ml and contain the escherichia coli of shuttle expression carrier and contain conjugative plasmid RP4 and the escherichia coli of helper plasmid pRL528,37 ℃ are shaken bacterium and spend the night.The centrifugal 5min of 4000rpm receives bacterium, is resuspended in the common LB culture fluid of 5ml.Equal-volume mixes two kinds of bacterium liquid.

B. the preparation of cyanophyceae:

The cyanophyceae culture is used the culture fluid washed twice in the centrifugal 2min collecting cell of 4000rpm, again with the culture fluid suspension frustule of proper volume.

C. conduction

With frustule be applied on the mixed cellulose ester microporous membrane after antibacterial mixes, after cultivating 2 days on the solid medium of antibiotic-free, place and continue illumination cultivation on the culture medium that contains ammonia benzyl and streptomycin and occur until transformant.

2. screen and amplification culture transgenic ocean Synechococcus

Change the transformant that obtains over to Medium A culture fluid and wherein contain ammonia benzyl and streptomycin, continue screening and progressively enlarge the liquid culture volume, after molecular Biological Detection, determine whether to obtain changeing the ocean Synechococcus of hTNF-α gene.The ocean Synechococcus of the conversion that obtains is deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center (CGMCC) (China, Beijing, Zhong Guan-cun) on October 20th, 2000, and preserving number is CGMCC 0499.

The preparation of five products

The ocean Synechococcus centrifugal (rotating speed 6000r/min) that the growth later stage changes hTNF-α gene of taking the logarithm is received algae, with buffer washing precipitation 2 times, add the resuspended precipitation of lysate (50mmol Tris-Cl PH8.0), with frozen-thawed 3 times, in the ice bath ultrasonic 10 times (each 15-20s), this extract of lyophilization.The lyophilization oral capsule (100mg/ capsule) of quantitatively packing into is contained the pure hTNF-α of 100 μ g approximately, except that the frustule material, do not contain other additives.Preferably be kept in the low temperature, do not find loss of activity at room temperature 15 days.

The cytotoxic activity of six transgenic ocean Synechococcus expression products

The present invention successfully transforms the single-cell sea Synechococcus with pKT-hTNF alpha expression carrier, has obtained the transgenic blue algae of the human tumour necrosis factor (hTNF α) of stably express.This experiment is determined the biologic activity of its expression product and is identified its external drug effect by detecting the cytotoxic activity that changes hTNF α in the hTNF gene blue algae expression product.

1.hTNF the extraction of gene ocean Synechococcus expression product

1) crude extract preparation

In the centrifugal receipts of frustule logarithmic growth middle and late stage algae, wash 2 times with buffer, remove culture fluid ,-20 ℃ of cold preservations are standby.During preparation frustule is dissolved in buffer, through the liquid nitrogen multigelation, the ice-water bath ultrasonication.The centrifugal supernatant crude extract that gets.

2) EAE52 cellulose ion-exchange chromatography

The DEAE52 cellulose ion-exchange chromatography, post specification 2cm * 30cm uses the eluent balance.Above-mentioned crude extract precipitates through the sulfur ammonium, solution dialysis back upper prop, and respectively with 0M, 0.1M, 0.3MNaCl stepwise elution.Active peak, dialysis, vacuum lyophilization that collection contains hTNF α concentrate.

2. change hTNF gene ocean Synechococcus extract biologic activity

Adopt conventional L929 cytotoxicity test, (method is referring to document Bryan T.Spofford to detect the TNF activity, Raymond A.Daynes, Gale A.Granger, Cell-mediated immunityin vitro:A highly sensitive assay for human lymphotoxin J.Immunol.1974,112,6).

L929 cell line (1-3 * 10 ⁴Cells/well [PRMI 1640+10% calf serum, 0.2ml]), be seeded on the 96 hole plastic culture plates, 37 ℃, 5%CO ₂Overnight incubation (18hr).Abandon clean culture fluid, adding final concentration is 0.4 μ g/ml actinomycin D, each 50 μ l of different dilution oceans Synechococcus extract sample, and each concentration is established 3 parallel holes, and 37 ℃ are continued insulation, observation of cell survival condition behind the 18hr.

Abandon specimen, and cell 0.1ml 0.2% crystal violet ethanol-water solution (2: 98, V/V) room temperature dyeing 10min uses the distilled water flushing culture plate, and room temperature is dried.Add 0.1ml 1%SDS solution cell lysis, on enzyme-linked immunosorbent assay instrument, select OD630 to measure light absorption value A, calculate every cell mean and survival rate.

% cytotoxic activity=1-(A _Experiment-A _Background)/(A _Contrast-A _Background)

With the hTNF-α dilution factor that kills 50% cell is an active unit.

3. the cytotoxic activity of crude extract

The crude extract protein concentration is 5.472mg/ml, and sample is done different dilution factors and handled, and adds 96 orifice plates (2～30,000 cells/well) and handles back mensuration absorbance.Calculation sample is to L929 cell inhibiting rate, according to formula to calculating active unit.Show cytotoxic activity 100U/mg frustule.

Seven. change hTNF α gene ocean Synechococcus 7002 goods anti-tumor in vivo activity

1. detect the antitumor activity of oral commentaries on classics hTNF α gene Synechococcus 7002 goods with conventional method to mice transplantable tumor sarcoma S180 solid tumor.The blank group is set up in test separately, changes empty carrier beads algae and two kinds of dosage commentaries on classics hTNF α gene beads algae product groups.Behind the healthy kunming mice inoculation oncocyte second day, oral administration gavage is given respectively changeed hTNF α gene beads algae product or changes empty carrier beads algae, and matched group gives 0.4ml normal saline, put to death animal after continuous 6～9 times, get tumor and weigh, calculate the heavy and suppression ratio of average tumor, and carry out statistical procedures.

2. carry out twice experiment, twice experimental result shows that all oral commentaries on classics hTNF α gene Lycoperdon polymorphum Vitt beads algae product has certain anti-tumor activity to mice S180 solid tumor.

Experiment was for the first time changeed hTNF α gene Lycoperdon polymorphum Vitt beads algae product 1.25g/kg/ days, and totally 9 times, to the tumour inhibiting rate of S180 solid tumor (the normal saline matched group tumor weight/medication group tumor weight=1.03g/0.55g) that can reach 46.6%.Experiment was for the second time changeed hTNF α gene Lycoperdon polymorphum Vitt beads algae product 2.5g/kg/ days, totally 6 times, can reach 35.3% to the tumour inhibiting rate of S180 solid tumor and (change empty carrier Synechococcus 7002 matched group tumor weight/medication group tumors weight=1.81g/1.26g), learn by statistics and handle, twice experiment P value is all less than 0.05, have significant difference, show that oral commentaries on classics hTNF α gene Synechococcus 7002 goods are effective to the S180 solid tumor.Simultaneously, experiment shows that changeing 7002 pairs of S180 growths of empty carrier Synechococcus does not have influence.

Eight. change the chmice acute toxicity of hTNF gene ocean Synechococcus 7002 goods

1.hTNF α gene Synechococcus 7002 (wild algae kind gets institute from French Bath) is the transgenic Synechococcus 7002 (numbering N12) that transforms and obtain 2 years hTNF of stably express with the pIB-01 expression vector, identifies that through cytotoxicity test and immunological method it has biologic activity.A large amount of cultivate the N12 cyanophyceaes, collect frustule, with distilled water flush away culture fluid after the ultrasonication postlyophilization is made dry powder.

20 of the healthy kunming mices of no pathogenic bacteria, body weight 18-22g, male and female half and half provide (this animal housing obtains " Beijing's zoopery licence ", and used kind of Mus obtained the clean animal quality certification) by Tumour Inst., Chinese Medical Academy experimental animal chamber.

2. acute toxicity test is meant in the animal one day after the single or multiple administration in 7 days or 14 days, the toxic reaction and the death condition of observing animal continuously and being produced.Toxicity was estimated requirement before China was clinical, and the route of administration of acute toxicity test has at least a kind of consistent with the clinical administration approach.The observation of toxicity test should be carried out from qualitative and quantitative two aspects.So-called qualitative observation is exactly the poisoning manifestations etc. of observing the back animal of taking medicine.So-called quantitative observation is exactly the relation of observing animal toxicity reaction and dosage, leading indicator: and median lethal dose(LD 50) (lethal dose 50, LD50).When some medicine gives animal with maximum acceptable concentration and maximum permission capacity, do not measure LD50 yet, can only demand the MTD value, after promptly once giving 20 mices with Cmax and maximum permission capacity, observed 7-14 days continuously, do not see any animal dead, then MTD＞XXg/kg.(referring to " and new drug clinical before safety evaluatio with put into practice ")

This experimental evidence trial test result belongs to latter event.Therefore adopt the N12 freeze-dried product of Cmax (25%, promptly 25g dry powder is dissolved in the 100ml physiological saline solution), give mouse stomach with the volume of 0.2ml/10g body weight.Observed variations such as mice body weight, active situation, hair, feces, appetite after the administration in continuous 14 days and write down dead quantity timely between.

3. after oral administration (N12 goods) the 5g/kg body weight, 20 of observations in continuous 14 days are tried mice, and none is only dead, movable normal, well-grown, and weight increase is to 28-38g.

4. result of the test shows: change hTNF α gene Synechococcus goods preparation Cmax (25%), once give 20 mices, and oral administration administration (po), animal does not produce death.Record maximum tolerated dose (MTD)＞5g/kg.FDA thinks, if add＞can be considered nontoxic during 5g/kg.Therefore, judge transgenic Synechococcus 7002 goods of this hTNF α, the mice oral administration is not shown toxicity.

Claims (4)

1. Orally applied medicine containing Nostoc which expressing human tumor necrosin factor alpha contains the ocean Synechococcus (Synecoccucs sp.) of expressing human tumor necrosis factor.

2. according to the described oral agents of claim 1, wherein said ocean Synechococcus is ocean Synechococcus 7002 (Synecoccucs sp.PCC 7002).

3. oral agents according to claim 1, wherein, the cDNA of this tumor necrosis factor of encoding has the nucleotide sequence shown in following:

5’ATG GTT CGT TCT TCT TCT CGT ACC CCG AGT GAC AAG CCT GTA GCC CAT GTT GTA

GCA AAC CCT CAA GCT GAG GGG CAG CTC CAG TGG CTG AAC CGC CGG GCC AAT GCC

CTC CTG GCC AAT GGC GTG GAG CTG AGA GAT AAC CAG CTG GTG GTG CCA TCA GAG

GGC CTG TAC CTC ATC TAC TCC CAG GTC CTC TTC AAG GGC CAA GGC TGC CCC TCC

ACC CAT GTG CTC CTC ACC CAC ACC ATC AGC CGC ATC GCC GTC TCC TAC CAG ACC

AAG GTC AAC CTC CTC TCT GCC ATC AAG AGC CCC TGC CAG AGG GAG ACC CCA GAG

GGG GCT GAG GCC AAG CCC TGG TAT GAG CCC ATC TAT CTG GGA GGG GTC TTC CAG

CTG GAG AAG GGT GAC CGA CTC AGC GCT GAG ATC AAT CGG CCC GAC TAT CTC GAC

TTT GCC GAG TCT GGG CAG GTC TAC TTT GGG ATC ATT GCC CTG TGA 3’

4. according to the described oral agents of claim 1, wherein, the ocean Synechococcus of described expressing human tumor necrosis factor is CGMCC 0499.

Images